A Phase II study of intravenous 6-thioguanine (NSC-752) in advanced colorectal carcinoma

J. Rubin, A. J. Schutt, Henry Clement Pitot

Research output: Contribution to journalArticle

Abstract

Fifteen patients with advanced measurable colorectal carcinoma were treated with intravenous 6-thioguanine (6-TG) at a dosage of 55 mg/m2 for 5 consecutive days every 5 weeks. Only one patient had received prior adjuvant chemotherapy. No responses were detected, and eight patients had stable disease for a median duration of three treatment cycles. Toxicity was tolerable. We conclude that 6-TG given by this dosage schedule is ineffective in treating metastatic colorectal carcinoma.

Original languageEnglish (US)
Pages (from-to)236-238
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume15
Issue number3
StatePublished - 1992

Fingerprint

Thioguanine
Colorectal Neoplasms
Adjuvant Chemotherapy
Appointments and Schedules
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A Phase II study of intravenous 6-thioguanine (NSC-752) in advanced colorectal carcinoma. / Rubin, J.; Schutt, A. J.; Pitot, Henry Clement.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 15, No. 3, 1992, p. 236-238.

Research output: Contribution to journalArticle

@article{720e00be7a37403ba3b032bb49f12735,
title = "A Phase II study of intravenous 6-thioguanine (NSC-752) in advanced colorectal carcinoma",
abstract = "Fifteen patients with advanced measurable colorectal carcinoma were treated with intravenous 6-thioguanine (6-TG) at a dosage of 55 mg/m2 for 5 consecutive days every 5 weeks. Only one patient had received prior adjuvant chemotherapy. No responses were detected, and eight patients had stable disease for a median duration of three treatment cycles. Toxicity was tolerable. We conclude that 6-TG given by this dosage schedule is ineffective in treating metastatic colorectal carcinoma.",
author = "J. Rubin and Schutt, {A. J.} and Pitot, {Henry Clement}",
year = "1992",
language = "English (US)",
volume = "15",
pages = "236--238",
journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - A Phase II study of intravenous 6-thioguanine (NSC-752) in advanced colorectal carcinoma

AU - Rubin, J.

AU - Schutt, A. J.

AU - Pitot, Henry Clement

PY - 1992

Y1 - 1992

N2 - Fifteen patients with advanced measurable colorectal carcinoma were treated with intravenous 6-thioguanine (6-TG) at a dosage of 55 mg/m2 for 5 consecutive days every 5 weeks. Only one patient had received prior adjuvant chemotherapy. No responses were detected, and eight patients had stable disease for a median duration of three treatment cycles. Toxicity was tolerable. We conclude that 6-TG given by this dosage schedule is ineffective in treating metastatic colorectal carcinoma.

AB - Fifteen patients with advanced measurable colorectal carcinoma were treated with intravenous 6-thioguanine (6-TG) at a dosage of 55 mg/m2 for 5 consecutive days every 5 weeks. Only one patient had received prior adjuvant chemotherapy. No responses were detected, and eight patients had stable disease for a median duration of three treatment cycles. Toxicity was tolerable. We conclude that 6-TG given by this dosage schedule is ineffective in treating metastatic colorectal carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0026696071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026696071&partnerID=8YFLogxK

M3 - Article

C2 - 1590277

AN - SCOPUS:0026696071

VL - 15

SP - 236

EP - 238

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

SN - 0277-3732

IS - 3

ER -